Table 2 Clinical and epidemiologic characteristics of the 63 (out of 68) Mediterranean CL patients for who the Leishmania species was identified

Median age years [IQ25–IQ75]

39 [16.3–56.5]

42 [12–57]

56 [22–56]

Sex ratio (M/F)

1.66

1.25

2

Median length of stay in endemic area days [IQ25-IQ75]

60 [30–90]

60 [48–60]

45 [30–75]

Occurrence of skin lesions (n/data available)

 During the stay

12/38 (32%)

2/8 (25%)

2/4 (50%)

  ≤ 30 days after the return

16/38 (42%)

2/8 (25%)

1/4 (25%)

  > 1 to ≤ 3 months

8/38 (21%)

3/8 (37%)

0/4 (0%)

  > 3 months

2/38 (5%)

1/8 (13%)

1/4 (25%)

Median days before seeking medical advice [IQ25-IQ75]

90 [60–103]

90 [90–12]

180 [128–255]

Number of lesions (n/data available)

 Unique

18/47 (38%)

5/9 (56%)

3/6 (50%)

 Multiple

29/47 (62%)

4/9 (44%)

3/6 (50%)

Localization of lesions (n/data available)

 Limb (at least one lesion)

37/46 (80%)

3/9 (33%)

3/6 (50%)

 Face (at least one lesion)

9/46 (20%)

6/9 (67%)

3/6 (50%)

Crusted ulcero-necrotic lesions

44/48 (92%)

6/9 (67%)

1/6 (17%)

Country of contamination

 North- Africa (n = 37)

24/37 (65%)

9/37 (24%)

4/37 (11%)

  Algeria (n = 4)

2/4

–

2/4

  Morocco (n = 8)

4/8

2/8

2/8

  Tunisia (n = 25)

18/25

7/25

–

 Sub-Saharan Africa (n = 20)

20/20 (100%)

–

–

  Mali (n = 3)

3/3

–

–

  Mauritania (n = 6)

6/6

–

–

  Senegal (n = 11)

11/11

–

–

Middle East (n = 4)

4/4 (100%)

–

–

 Egypt (n = 1)

1/1

–

–

 Israel (n = 3)

3/3

–

–

Europe (n = 2)

–

–

2/2 (100%)

 Spain (n = 2)

–

–

2/2